3Hieble J P,Bylund DB,Clarke DE,et al.InternationalUnion of Pharmacology.X Recommentdation fornomenclature of a-adrenoreceptor:Consensus Update.Pharmacol Rev 1995;47:267.
4Foglar R,Shibata K,Horie K,et al.Use of recombi2nant α-adrenoreceptrosto characterize subtype selectiv2ity of drugs for the treatment of prostatichypertrophy.Eur J Pharmacol Mol Pharmacol 1995;288:201.
5Hatano A,Takahashi H,Tamaki M,et al.Pharmaco21ogical evidence of distincta-adrenoreceptor subtypesmediating the contraction of human prostatic urethraandperipheral artery.Br J Pharmacol 1994;113:732.
6Chapple CR,Wyndacle JJ,Nordling J,et al.Tamsu21osin,the first prostate-selective alpha lA-adrenore2ceptor antagonist.A metaanalysis of two randomized,placebo-controlled,multicentre studies in patients withbenign prostatic obstruction(symptomatic BPH)EurUrol 1996;29(2):155.
7Lee E,Lee C.Clinical comparison of selective and non-selective A-adrenoreceptor antagonists in benignprostatic hyperplasia:studies on tamsulosin in a fixeddose and terazosin in increasing doses.Br J Urol 1997;80:606.
